HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intraperitoneal taxanes.

Abstract
The taxanes appear to be promising agents for intraperitoneal use. Paclitaxel is currently undergoing Phase III investigation for the treatment of ovarian cancer. Docetaxel requires further Phase II study, but its impressive activity with systemic administration may be optimized with intraperitoneal administration for the treatment of peritoneal surface malignancy.
AuthorsFaheez Mohamed, Paul H Sugarbaker
JournalSurgical oncology clinics of North America (Surg Oncol Clin N Am) Vol. 12 Issue 3 Pg. 825-33 (Jul 2003) ISSN: 1055-3207 [Print] United States
PMID14567034 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel
  • Paclitaxel
Topics
  • Antineoplastic Agents, Phytogenic (pharmacokinetics, therapeutic use)
  • Biological Availability
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase II as Topic
  • Docetaxel
  • Dose-Response Relationship, Drug
  • Female
  • Gastrointestinal Neoplasms (drug therapy, pathology, surgery)
  • Humans
  • Infusions, Parenteral
  • Male
  • Maximum Tolerated Dose
  • Paclitaxel (pharmacokinetics, therapeutic use)
  • Risk Assessment
  • Sensitivity and Specificity
  • Taxoids (pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: